ATE192339T1 - Verwendung von fulleren-derivaten in diagnostischen und/oder therapeutischen mitteln - Google Patents

Verwendung von fulleren-derivaten in diagnostischen und/oder therapeutischen mitteln

Info

Publication number
ATE192339T1
ATE192339T1 AT93904187T AT93904187T ATE192339T1 AT E192339 T1 ATE192339 T1 AT E192339T1 AT 93904187 T AT93904187 T AT 93904187T AT 93904187 T AT93904187 T AT 93904187T AT E192339 T1 ATE192339 T1 AT E192339T1
Authority
AT
Austria
Prior art keywords
diagnostic
pct
therapeutic agents
fullerene derivatives
sec
Prior art date
Application number
AT93904187T
Other languages
English (en)
Inventor
Alan D Watson
Jo Klaveness
Gene C Jamieson
Jere Douglas Fellmann
Nils Blane Vogt
Julian R M Cockbain
Original Assignee
Nycomed Salutar Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Salutar Inc filed Critical Nycomed Salutar Inc
Application granted granted Critical
Publication of ATE192339T1 publication Critical patent/ATE192339T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1268—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules host-guest, closed hollow molecules, inclusion complexes, e.g. with cyclodextrins, clathrates, cavitates, fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/009—Neutron capture therapy, e.g. using uranium or non-boron material
    • A61K41/0095—Boron neutron capture therapy, i.e. BNCT, e.g. using boronated porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
    • A61K49/0084—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion liposome, i.e. bilayered vesicular structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0438—Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/189—Host-guest complexes, e.g. cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasonic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasonic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/228—Host-guest complexes, clathrates, chelates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/927—Diagnostic contrast agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Acoustics & Sound (AREA)
  • Optics & Photonics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Medicinal Preparation (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
AT93904187T 1992-02-11 1993-02-11 Verwendung von fulleren-derivaten in diagnostischen und/oder therapeutischen mitteln ATE192339T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929203037A GB9203037D0 (en) 1992-02-11 1992-02-11 Contrast agents
PCT/GB1993/000279 WO1993015768A1 (en) 1992-02-11 1993-02-11 Use of fullerenes in diagnostic and/or therapeutic agents

Publications (1)

Publication Number Publication Date
ATE192339T1 true ATE192339T1 (de) 2000-05-15

Family

ID=10710315

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93904187T ATE192339T1 (de) 1992-02-11 1993-02-11 Verwendung von fulleren-derivaten in diagnostischen und/oder therapeutischen mitteln

Country Status (8)

Country Link
US (1) US5688486A (de)
EP (1) EP0625055B1 (de)
JP (1) JPH07506092A (de)
AT (1) ATE192339T1 (de)
AU (1) AU3506893A (de)
DE (1) DE69328550T2 (de)
GB (1) GB9203037D0 (de)
WO (1) WO1993015768A1 (de)

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5248498A (en) * 1991-08-19 1993-09-28 Mallinckrodt Medical, Inc. Fullerene compositions for magnetic resonance spectroscopy and imaging
WO1994005671A1 (de) * 1992-09-08 1994-03-17 Hoechst Aktiengesellschaft Neue fulleren-derivate, verfahren zur herstellung und deren verwendung
DE4339053A1 (de) * 1992-12-15 1994-06-16 Franz Dietrich Oeste Mit Wirkstoffen gefüllte Spheren, Verfahren zu ihrer Herstellung und Öffnung
JPH09503765A (ja) * 1993-10-04 1997-04-15 マリンクロット・メディカル・インコーポレイテッド 磁気共鳴イメージング、ｘ線イメージング、および放射性医薬品用組成物および方法
US5866434A (en) * 1994-12-08 1999-02-02 Meso Scale Technology Graphitic nanotubes in luminescence assays
WO1996024139A2 (en) * 1995-01-23 1996-08-08 Schaefer Daniel R Trapping and storage of free thermal neutrons in fullerene molecules
RU2186405C2 (ru) * 1996-03-29 2002-07-27 Лоренс Беркли Нэшнл Лэборэтори Усиление ядерного магнитного резонанса (ямр) и магниторезонансной визуализации (мрв) в присутствии гиперполяризованных благородных газов
US6736769B2 (en) 1996-04-17 2004-05-18 Olivier Bertrand Radioactivity local delivery system
US5871436A (en) * 1996-07-19 1999-02-16 Advanced Cardiovascular Systems, Inc. Radiation therapy method and device
US5782740A (en) * 1996-08-29 1998-07-21 Advanced Cardiovascular Systems, Inc. Radiation dose delivery catheter with reinforcing mandrel
US6210312B1 (en) 1997-05-20 2001-04-03 Advanced Cardiovascular Systems, Inc. Catheter and guide wire assembly for delivery of a radiation source
WO1999004826A1 (en) * 1997-07-24 1999-02-04 The Australian National University Method for detection of fibrin clots
AU1922799A (en) 1997-12-19 1999-07-12 Cordis Corporation Catheter system having fullerenes and method
US6159140A (en) * 1998-02-17 2000-12-12 Advanced Cardiovascular Systems Radiation shielded catheter for delivering a radioactive source and method of use
US6159139A (en) * 1998-02-17 2000-12-12 Advanced Cardiovascular Systems Inc. Radiation delivery catheter with a spring wire centering mechanism
DE19816917A1 (de) * 1998-04-16 1999-10-28 Siemens Ag Verfahren zur räumlich aufgelösten Temperaturüberwachung, Suspension von ferromagnetischen Mikropartikeln und Verwendung dieser Suspension
GB2337050B (en) * 1998-05-04 2001-02-14 Chinese Petroleum Corp Fullerene-containing metallocene
WO2000006244A2 (en) * 1998-07-30 2000-02-10 Hainfeld James F Loading metal particles into cell membrane vesicles and metal particle use for imaging and therapy
US6355224B1 (en) 1998-09-17 2002-03-12 Massachusetts Institute Of Technology Conductive polymer contrast agent compositions and uses therefor
CA2350882C (en) 1998-11-12 2011-02-22 Life Technologies Corporation Transfection reagents
US6203778B1 (en) * 1998-12-08 2001-03-20 The Regents Of The University Of California Particulate radiopaque contrast agent for diagnostic imaging and microvascular characterization
US20030073250A1 (en) * 1999-05-21 2003-04-17 Eric Henderson Method and apparatus for solid state molecular analysis
US6573369B2 (en) * 1999-05-21 2003-06-03 Bioforce Nanosciences, Inc. Method and apparatus for solid state molecular analysis
US20020042081A1 (en) * 2000-10-10 2002-04-11 Eric Henderson Evaluating binding affinities by force stratification and force panning
US20030186311A1 (en) * 1999-05-21 2003-10-02 Bioforce Nanosciences, Inc. Parallel analysis of molecular interactions
US6562295B1 (en) * 1999-06-30 2003-05-13 Ceramoptec Industries, Inc. Bacteria resistant medical devices
DE19936997B4 (de) * 1999-08-02 2007-06-14 Biolitec Ag Verfahren zur Applikation von Photosensibilisatoren (PS) mittels Multiplikatoren in der photodymamischen Therapie
US6582417B1 (en) 1999-09-22 2003-06-24 Advanced Cardiovascular Systems, Inc. Methods and apparatuses for radiation treatment
US6605031B1 (en) 1999-09-22 2003-08-12 Advanced Cardiovascular Systems, Inc. Stepped centering balloon for optimal radiation delivery
US6355225B1 (en) * 1999-10-05 2002-03-12 Wm. Marsh Rice University Tda Research, Inc. Fullerene contrast agent for magnetic resonance imaging and spectroscopy
US7897140B2 (en) 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
US7163504B1 (en) 2000-02-16 2007-01-16 Advanced Cardiovascular Systems, Inc. Multi-lumen fluted balloon radiation centering catheter
US7994449B2 (en) 2000-02-16 2011-08-09 Advanced Cardiovascular Systems, Inc. Square-wave laser bonding
US6897015B2 (en) * 2000-03-07 2005-05-24 Bioforce Nanosciences, Inc. Device and method of use for detection and characterization of pathogens and biological materials
US8460367B2 (en) * 2000-03-15 2013-06-11 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US20070055367A1 (en) * 2000-03-15 2007-03-08 Orbus Medical Technologies, Inc. Medical device with coating that promotes endothelial cell adherence and differentiation
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
WO2001068158A1 (en) * 2000-03-15 2001-09-20 Orbus Medical Technologies Inc. Coating that promotes endothelial cell adherence
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US20030229393A1 (en) * 2001-03-15 2003-12-11 Kutryk Michael J. B. Medical device with coating that promotes cell adherence and differentiation
US6471942B1 (en) 2000-04-20 2002-10-29 Luna Innovations, Inc. Imaging and treatment method for body
JP2003532648A (ja) * 2000-05-02 2003-11-05 ハーン−マイトネル−インスチツート ベルリン ゲゼルシャフト ミット ベシュレンクテル ハフツング 構造形成した分子配列及び量子力学的情報処理のためのその使用
WO2001089379A1 (en) * 2000-05-21 2001-11-29 Transscan Medical Ltd. Apparatus for impedance imaging coupled with another modality
US6652833B2 (en) * 2000-07-13 2003-11-25 The Regents Of The University Of California Functionalized active-nucleus complex sensor
US7061237B2 (en) * 2000-07-13 2006-06-13 The Regents Of The University Of California Remote NMR/MRI detection of laser polarized gases
US20030165431A1 (en) * 2000-07-13 2003-09-04 The Regents Of The University Of California Method for detecting macromolecular conformational change and binding information
DE60135150D1 (de) * 2000-08-15 2008-09-11 Bioforce Nanosciences Inc Vorrichtung zur bildung von nanomolekularen netzwerken
WO2002051301A2 (en) * 2000-11-10 2002-07-04 Wm. Marsh Rice University Fullerene (c60)-based x-ray contrast agent for diagnostic imaging
US20020177769A1 (en) * 2001-04-23 2002-11-28 The Regents Of The University Of California Method and apparatus for locating cells in the body by measuring magnetic moments
US20040038946A1 (en) * 2001-04-27 2004-02-26 Wilson Lon J. Fullerene-based drugs targeted to bone
US6878361B2 (en) * 2001-07-10 2005-04-12 Battelle Memorial Institute Production of stable aqueous dispersions of carbon nanotubes
WO2003008941A2 (en) * 2001-07-17 2003-01-30 Bioforce Nanosciences, Inc. Combined molecular blinding detection through force microscopy and mass spectrometry
US20040156852A1 (en) * 2003-02-06 2004-08-12 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles
US7042488B2 (en) 2001-09-27 2006-05-09 Fujinon Corporation Electronic endoscope for highlighting blood vessel
AU2002334784A1 (en) 2001-10-01 2003-04-14 Tda Research, Inc. Derivatization and solubilization of insoluble classes of fullerenes
US7812190B2 (en) 2001-10-01 2010-10-12 Tda Research, Inc. Derivatization and solubilization of fullerenes for use in therapeutic and diagnostic applications
US20030135195A1 (en) * 2002-01-16 2003-07-17 Oscar Jimenez Highly lubricious hydrophilic coating utilizing dendrimers
ES2233118B1 (es) * 2002-01-30 2006-07-16 Francisco Leon Prieto Sistema de administracion no intravenosa de un ligando especifico de celulas de epitelios, detectable por tecnicas de imagen y sus aplicaciones.
TW200307563A (en) * 2002-02-14 2003-12-16 Sixty Inc C Use of BUCKYSOME or carbon nanotube for drug delivery
US20080193490A1 (en) * 2002-02-14 2008-08-14 Andreas Hirsch Use of Carbon Nanotube for Drug Delivery
US20040166152A1 (en) * 2002-02-14 2004-08-26 Andreas Hirsch Use of buckysome or carbon nanotube for drug delivery
JP2005522471A (ja) * 2002-04-02 2005-07-28 バージニア テック インテレクチュアル プロパティーズ インコーポレーテッド 金属内包フラーレン造影剤
JP4667705B2 (ja) * 2002-04-26 2011-04-13 三菱電機株式会社 磁気的相互作用算出プログラム
US20050239193A1 (en) * 2002-05-30 2005-10-27 Bioforce Nanosciences, Inc. Device and method of use for detection and characterization of microorganisms and microparticles
WO2003105762A2 (en) * 2002-06-14 2003-12-24 Actinium Pharmaceuticals Ltd. Treating disease using radium-225
WO2004002476A2 (en) 2002-06-27 2004-01-08 Health Research, Inc. Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy
US7053210B2 (en) 2002-07-02 2006-05-30 Health Research, Inc. Efficient synthesis of pyropheophorbide a and its derivatives
US20040058457A1 (en) * 2002-08-29 2004-03-25 Xueying Huang Functionalized nanoparticles
US20040092807A1 (en) * 2002-11-07 2004-05-13 Amos Breskin System and method for cancer detection
WO2004060044A2 (en) * 2003-01-02 2004-07-22 Bioforce Nanosciences, Inc. Method and apparatus for molecular analysis in small sample volumes
US20040156846A1 (en) * 2003-02-06 2004-08-12 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles using L6 antibodies
RU2223118C1 (ru) * 2003-04-22 2004-02-10 Центральный научно-исследовательский рентгено-радиологический институт Способ получения [1-11c]-ацетата натрия
KR100513089B1 (ko) 2003-09-23 2005-09-08 광주과학기술원 풀러렌계 나노구 및 그 제조방법
US20060247152A1 (en) * 2005-05-02 2006-11-02 Russ Lebovitz Substituted fullerenes and their use as inhibitors of cell death
US20050288236A1 (en) * 2003-10-10 2005-12-29 Russ Lebovitz Substituted fullerene formulations and their use in ameliorating oxidative stress diseases or inhibiting cell death
US7410699B2 (en) * 2003-10-10 2008-08-12 Japan Science And Technology Agency Finely particulate composite containing carbon compound encapsulated in a polymer micelle of a block copolymer
GB2413182A (en) * 2004-04-16 2005-10-19 Univ Southampton An NMR method for analysing a sample
WO2005107817A2 (en) * 2004-04-30 2005-11-17 Orbus Medical Technologies, Inc. Medical device with coating for capturing genetically-altered cells and methods of using same
US20060039521A1 (en) 2004-06-22 2006-02-23 Schaefer Daniel R Direct production of thermal antineutrons and antiprotons
WO2006017333A2 (en) * 2004-07-13 2006-02-16 William Marsh Rice University Shortened carbon nanotubes
US20060280785A1 (en) * 2004-08-11 2006-12-14 Easterly Clay E Biocidal materials for treatment against pathogens
WO2006028635A2 (en) * 2004-09-02 2006-03-16 C Sixty Inc. Fullerene compositions for ameliorating hearing loss, collateral damage of chemotherapy, or mucositis
JP4822702B2 (ja) * 2004-12-24 2011-11-24 独立行政法人科学技術振興機構 造影剤
US20060140867A1 (en) * 2004-12-28 2006-06-29 Helfer Jeffrey L Coated stent assembly and coating materials
EP1830902A2 (de) * 2004-12-30 2007-09-12 Cinvention Ag Kombination aus einem mittel, das ein signal abgibt, implantatmaterial und arzeimittel
EP2014708A1 (de) 2005-01-13 2009-01-14 Cinvention Ag Geformter Körper aus einem Verbundstoffmaterial
DE102005005704B4 (de) * 2005-02-03 2010-08-12 Leibniz-Institut Für Festkörper- Und Werkstoffforschung Dresden E.V. Verwendung von Partikeln für die Ermittlung der lokalen Temperatur in organischen und nichtorganischen Körpern
DE102005007223B4 (de) * 2005-02-15 2009-01-02 Helmholtz-Zentrum Berlin Für Materialien Und Energie Gmbh Verwendung eines endohedrale Fullerene enthaltendes Kontrastmittel für die Kernspintomographie unter Nutzung des Overhauser-Effekts
WO2006116021A2 (en) * 2005-04-22 2006-11-02 Intematix Corporation Mri technique based on electron spin resonance and endohedral contrast agent
PT1877105E (pt) 2005-04-29 2013-11-11 Univ Australian Método para formar uma composição radioativa injetável de partículas radioativas encapsuladas em carbono
US8246917B2 (en) 2006-06-23 2012-08-21 Johns Hopkins University Self-assembled, micropatterned, and radio frequency (RF) shielded biocontainers and their uses for remote spatially controlled chemical delivery
US8236259B2 (en) * 2005-07-22 2012-08-07 Johns Hopkins University Self-assembled, micropatterned, and radio frequency (RF) shielded biocontainers
WO2008108862A2 (en) * 2006-06-23 2008-09-12 Johns Hopkins University Self-assembled, micropatterned, and radio frequency (rf) shielded biocontainers and their uses for remote spatially controlled chemical delivery
US20070025918A1 (en) * 2005-07-28 2007-02-01 General Electric Company Magnetic resonance imaging (MRI) agents: water soluble carbon-13 enriched fullerene and carbon nanotubes for use with dynamic nuclear polarization
AU2006303324A1 (en) * 2005-10-18 2007-04-26 Cinvention Ag Thermoset particles and methods for production thereof
US20080020977A1 (en) * 2005-11-21 2008-01-24 Russ Lebovitz Use of Fullerenes to Oxidize Reduced Redox Proteins
WO2007124038A2 (en) 2006-04-20 2007-11-01 Dentatek Corporation Apparatus and methods for treating root canals of teeth
US10835355B2 (en) 2006-04-20 2020-11-17 Sonendo, Inc. Apparatus and methods for treating root canals of teeth
WO2007137256A2 (en) * 2006-05-22 2007-11-29 William Marsh Rice University Carbon nanotube based imaging agents
ATE524197T1 (de) * 2006-05-25 2011-09-15 Univ Wake Forest Health Sciences Hyperthermische techniken und ihre therapeutische anwendung
WO2007143558A1 (en) * 2006-06-01 2007-12-13 William Marsh Rice University Targeted nanostructures for cellular imaging
US20100330539A1 (en) * 2006-08-24 2010-12-30 Medical Dental Advance Technologies Group Periodontal treatment system and method
US12114924B2 (en) 2006-08-24 2024-10-15 Pipstek, Llc Treatment system and method
US20080070195A1 (en) * 2006-08-24 2008-03-20 Divito Enrico E Energetically activated biomedical nanotheurapeutics integrating dental and medical treatments and procedures
US7980854B2 (en) 2006-08-24 2011-07-19 Medical Dental Advanced Technologies Group, L.L.C. Dental and medical treatments and procedures
US20080213611A1 (en) * 2007-01-19 2008-09-04 Cinvention Ag Porous, non-degradable implant made by powder molding
EP2129768A2 (de) * 2007-02-28 2009-12-09 Cinvention Ag Grossflächiges kultivierungssystem mit oberflächenvergrösserndem substrat
CA2677722A1 (en) * 2007-02-28 2008-09-04 Cinvention Ag High surface cultivation system with filler
WO2008104588A1 (en) * 2007-02-28 2008-09-04 Cinvention Ag High surface cultivation system
WO2008104599A1 (en) * 2007-02-28 2008-09-04 Cinvention Ag High surface cultivation system bag
WO2008154043A2 (en) * 2007-06-14 2008-12-18 The Board Of Trustees Of The University Of Arkansas Near-infrared responsive carbon nanostructures
WO2009059215A1 (en) * 2007-10-31 2009-05-07 University Of Florida Research Foundation, Inc. Use of fullerenes in photoacoustic imaging
US8187221B2 (en) * 2008-07-11 2012-05-29 Nexeon Medsystems, Inc. Nanotube-reinforced balloons for delivering therapeutic agents within or beyond the wall of blood vessels, and methods of making and using same
GB0820309D0 (en) * 2008-11-06 2008-12-17 Middlesex University Higher Ed Detection of cancer
DE102008043654A1 (de) * 2008-11-11 2010-05-20 Leibniz-Institut Für Festkörper- Und Werkstoffforschung Dresden E.V. Diagnostisches und/oder therapeutisches Agens, Verfahren zu seiner Herstellung und Verwendung
JP5463548B2 (ja) * 2009-09-08 2014-04-09 学校法人福岡大学 超音波治療用リポソーム及び超音波治療促進用リポソーム
CN102724929B (zh) 2009-11-13 2016-04-13 索南多股份有限公司 用于牙科治疗的液体射流设备和方法
US9125942B2 (en) * 2010-01-19 2015-09-08 Northwestern University Paramagnetic metal-nanodiamond conjugates
DE102010020567A1 (de) * 2010-05-14 2011-11-17 Merck Patent Gmbh Metallkomplexe
WO2012027556A1 (en) * 2010-08-25 2012-03-01 William Marsh Rice University Nanostructures comprising radioisotopes and/or metals
US8888879B1 (en) 2010-10-20 2014-11-18 Us Synthetic Corporation Detection of one or more interstitial constituents in a polycrystalline diamond element by neutron radiographic imaging
EP3808306B1 (de) 2010-10-21 2023-12-27 Sonendo, Inc. Vorrichtung für endodontische behandlungen
US9085463B2 (en) 2011-01-17 2015-07-21 Marelle, Llc Water-soluble functionalized fullerenes
WO2012135550A1 (en) * 2011-03-30 2012-10-04 Luna Innovations Incorporated Biomarker-targeting contrast agents and their use in magnetic resonance imaging for detection of atherosclerotic plaque
EP2836156B1 (de) 2012-03-22 2024-04-17 Sonendo, Inc. Vorrichtung zur zahnreinigung
US10631962B2 (en) 2012-04-13 2020-04-28 Sonendo, Inc. Apparatus and methods for cleaning teeth and gingival pockets
ES2883954T3 (es) 2012-12-20 2021-12-09 Sonendo Inc Aparato de limpieza de dientes y de conductos radiculares
US10363120B2 (en) 2012-12-20 2019-07-30 Sonendo, Inc. Apparatus and methods for cleaning teeth and root canals
WO2014179619A2 (en) 2013-05-01 2014-11-06 Sonendo, Inc. Apparatus and methods for treating teeth
CA2911415A1 (en) 2013-06-26 2014-12-31 Sonendo, Inc. Apparatus and methods for filling teeth and root canals
KR101612514B1 (ko) * 2014-06-16 2016-04-14 포항공과대학교 산학협력단 에멀젼을 이용한 탄소 양자점의 제조 방법
US10806544B2 (en) 2016-04-04 2020-10-20 Sonendo, Inc. Systems and methods for removing foreign objects from root canals
CN109096118B (zh) * 2017-06-21 2021-07-30 北京福纳康生物技术有限公司 胺基富勒烯衍生物及其制备方法和应用
USD997355S1 (en) 2020-10-07 2023-08-29 Sonendo, Inc. Dental treatment instrument
USD1118938S1 (en) 2022-09-23 2026-03-17 Sonendo, Inc. Dental console

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5122363A (en) * 1990-12-07 1992-06-16 Board Of Regents, The University Of Texas System Zeolite-enclosed transistion and rare earth metal ions as contrast agents for the gastrointestinal tract
US5248498A (en) * 1991-08-19 1993-09-28 Mallinckrodt Medical, Inc. Fullerene compositions for magnetic resonance spectroscopy and imaging
US5177248A (en) * 1991-10-28 1993-01-05 Exxon Research And Engineering Company Process of forming polysubstituted fullerenes

Also Published As

Publication number Publication date
AU3506893A (en) 1993-09-03
GB9203037D0 (en) 1992-03-25
DE69328550T2 (de) 2001-02-08
JPH07506092A (ja) 1995-07-06
US5688486A (en) 1997-11-18
DE69328550D1 (de) 2000-06-08
EP0625055A1 (de) 1994-11-23
EP0625055B1 (de) 2000-05-03
WO1993015768A1 (en) 1993-08-19

Similar Documents

Publication Publication Date Title
DE69328550D1 (de) Verwendung von fulleren-derivaten in diagnostischen und/oder therapeutischen mitteln
CA2075060A1 (en) Novel vehicle gases and their use in medical preparations
ATE319823T1 (de) Bmp-12, bmp-13 und diese enthaltende sehne- induzierende zusammensetzungen
KR900009079A (ko) 비스(3,5-디-tert-부틸-4-히드록시페닐티오)메탄 함유 콜레스테롤 저하제겸 아테롬성 동맥 경화증 치료제
DE68919146D1 (de) Ausgewählte Stämme von Lactobacillus enthaltende pharmazeutische Zusammensetzungen.
NO308794B1 (no) Farmakologisk aktive pyridin-derivater, preparater inneholdende forbindelsene samt forbindelsenes anvendelse
BG103439A (bg) Подобрения в или във връзка с диагностични/лечебни средства
EP0675708A1 (de) Pharmazeutische und dermokosmetische mittel enthaltend pferdecolostrum.
CY1111863T1 (el) Αντισωματα εναντιον υποδοχεα θανατου 4 (dr4) και χρησεις αυτων
TR199902803T2 (xx) VCAM-1' in te�hisinin daralt�lmas� i�in bile�ikler ve metodlar.
EE9800223A (et) Fenantridiinid, neid sisaldavad ravimid ja nende kasutamine
DK0396404T3 (da) Farmaceutisk middel indeholdende loratadin, ibuprofen og pseudoephedrin
YU26691A (sh) BORNO KISELINSKI ADUKTI RENIJUM DIOKSIM I TEHNICIJUM-99 m DIOKSIM KOMPLEKSA I PRIBOR ZA MARKIRANJE SA TEHNICIJUMOM 99 m I/ILI RADIONUKLEIDOM RENIJUMA
DE69420967D1 (de) Lösung zur verwendung gegen den pilzbefall von nägeln
DE69429536D1 (de) Analgetisches Mittel und dessen Verwendung
DE69813839D1 (de) Verwendung von n,n-bis (phenylcarbamoylmethyl) dimethylammoniumchlorid und derivaten davon zur behandlung von chronischem schmerz
DE59511017D1 (de) [a]-ANNELIERTE PYRROLDERIVATE UND DEREN ANWENDUNG IN DER PHARMAZIE
EP0793660A4 (de) 2-substituierte 1,2,5-thiadiazolidin-3-on-1,1-dioxiden, zusammensetzung und deren verwendung
DK7191A (da) Topisk salve
DE69633985D1 (de) Behandlung von Chromoxid und dessen Verwendung in der katalytischen Herstellung von Vinylfluorid
GR1001151B (el) Νεα xρηση θειορεδοξινης
DK0478631T3 (da) Målsøgende midler
ES2080855T3 (es) Pirido-oxacinas sustituidas.
ZA849576B (en) 1,7-diphenyl-3-methyllaza-7-cyano-8-methylnonane for use in the treatment of diseases
DE69427116D1 (de) Verwendung von 4'-iodo - 4 - deoxydoxorubicin zur behandlung von amyloidosis

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties